ALASCCA is a prospective, randomized, double blinded, placebo controlled, multicenter, biomarker-based study of adjuvant treatment with ASA in colorectal cancer. A total of 3,900 patients will be screened. The primary objective of ALASCCA is to determine whether adjuvant treatment with 160 mg ASA once daily for 3 years can improve time to recurrence in patients with colorectal cancer with somatic alterations in the PI3K signaling pathway.